FULC
Fulcrum Therapeutics Inc

2,311
Mkt Cap
$468.87M
Volume
1,264.00
52W High
$15.74
52W Low
$2.32
PE Ratio
-5.96
FULC Fundamentals
Price
$7.04
Prev Close
$6.92
Open
$6.87
50D MA
$9.58
Beta
1.31
Avg. Volume
917,487.32
EPS (Annual)
-$1.18
P/B
1.34
Rev/Employee
$0.00
$370.68
Loading...
Loading...
News
all
press releases
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk
Fulcrum Therapeutics (NASDAQ:FULC) executives highlighted what they described as strong physician interest and encouraging clinical signals from the company's PIONEER study in sickle cell disease...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7%
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 27th, there was short interest totaling...
MarketBeat·3d ago
News Placeholder
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC
Boothbay Fund Management LLC raised its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 104.2% during the third quarter, according to its most recent disclosure with the...
MarketBeat·4d ago
News Placeholder
219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP
Braidwell LP acquired a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 219,488...
MarketBeat·5d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5% - Here's Why
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 7.5% - Here's Why...
MarketBeat·18d ago
News Placeholder
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report issued...
MarketBeat·22d ago
News Placeholder
Equities Analysts Issue Forecasts for FULC FY2030 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Fulcrum Therapeutics in a note issued to investors on...
MarketBeat·23d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - What's Next?
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - What's Next...
MarketBeat·24d ago
News Placeholder
Fulcrum Therapeutics Q4 Earnings Call Highlights
Fulcrum Therapeutics (NASDAQ:FULC) shared full 12-week results from the 20-mg cohort of its phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease, expanding on partial data...
MarketBeat·24d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Meets Expectations
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus...
MarketBeat·24d ago
<
1
2
...
>

Latest FULC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.